---
title: "Viking Therapeutics, Inc. (VKTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VKTX.US.md"
symbol: "VKTX.US"
name: "Viking Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T19:30:27.081Z"
locales:
  - [en](https://longbridge.com/en/quote/VKTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VKTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VKTX.US.md)
---

# Viking Therapeutics, Inc. (VKTX.US)

## Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.vikingtherapeutics.com](https://www.vikingtherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.97 | 411 | - | - | - |
| PB | 6.56 | 359 | 6.02 | 5.31 | 3.74 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 63% |
| Overweight | 5 | 26% |
| Hold | 2 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 29.37 |
| Highest Target | 125.00 |
| Lowest Target | 34.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VKTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VKTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VKTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VKTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**